First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

February 17, 2020

Primary Completion Date

March 16, 2022

Study Completion Date

March 16, 2022

Conditions
Healthy VolunteersOverweightObesityDiabetes Mellitus, Type 2
Interventions
DRUG

NNC0480-0389

Part 1: A single dose of NNC0480-0389, dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of NNC0480-0389, dose increased in each cohort.

DRUG

Semaglutide

Part 1: Single dose of semaglutide (0.5 mg). Part 2: Weekly doses of semaglutide alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.

DRUG

Placebo (NNC0480-0389)

Placebo for NNC0480-0389. Part 1: A single dose of placebo (NNC0480-0389), dose increased in each cohort. Part 2: Weekly doses (for 4 weeks) of placebo A, dose increased in each cohort.

DRUG

Placebo (semaglutide)

Part 1: Single dose of placebo (semaglutide) (0.5 mg). Part 2: Weekly doses of placebo (semaglutide) alone for 8 weeks (2 x 0.25 mg, 2 x 0.5 mg and 4 x 1 mg) followed by weekly fixed doses of 1 mg semaglutide for 4 weeks.

Trial Locations (1)

9728 NZ

Novo Nordisk Investigational Site, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY